Bristol-Myers Squibb Co
CELG_r0.046USD
+0.001+1.10%
收盘 12/24, 16:00（美东）报价延迟15分钟
0.00总市值
--市盈率 TTM
关于 Bristol-Myers Squibb Co 公司
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Co简介
公司代码CELG_r
公司名称Bristol-Myers Squibb Co
上市日期Mar 17, 1980
CEOBoerner (Christopher S)
员工数量- -
证券类型Right
年结日- -
公司地址Route 206 And Province Line Road
城市PRINCETON
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编08543
电话16092524621
网址https://www.bms.com
公司代码CELG_r
上市日期Mar 17, 1980
CEOBoerner (Christopher S)
Bristol-Myers Squibb Co公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Ms. Amanda Poole
Ms. Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Executive Vice President, Chief People Officer, Member of the Leadership Team
--
--
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert Plenge, M.D., Ph.D.
Mr. Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Mr. David V. Elkins
Mr. David V. Elkins
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Ms. Amanda Poole
Ms. Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Executive Vice President, Chief People Officer, Member of the Leadership Team
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月22日 周六
更新时间: 11月22日 周六
持股股东
股东类型
持股股东
持股股东
占比
其他
100.00%
持股股东
持股股东
占比
其他
100.00%
股东类型
持股股东
占比
其他
100.00%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
32
423.55K
0.00%
--
2025Q3
33
423.55K
0.00%
-91.51K
2025Q2
34
515.06K
0.00%
+32.24K
2025Q1
32
482.82K
0.00%
-636.30K
2024Q4
32
943.61K
0.00%
+342.07K
2024Q3
31
601.53K
0.00%
+90.03K
2024Q2
30
511.50K
0.00%
+113.76K
2024Q1
32
397.74K
0.00%
-298.70K
2023Q4
30
495.62K
0.00%
-40.30K
2023Q3
30
535.93K
0.00%
-7.05K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
International Assets Investment Management, LLC
175.00
0%
+175.00
--
Jun 30, 2024
Transcend Capital Advisors, LLC
109.17K
0%
--
--
Jun 30, 2025
Davenport Asset Management
83.97K
0%
--
--
Jun 30, 2025
BofA Global Research (US)
51.83K
0%
+10.00
+0.02%
Jun 30, 2025
Purkiss Capital Advisors LLC
26.45K
0%
--
--
Jun 30, 2025
Two Sigma Investments, LP
21.99K
0%
-3.69K
-14.36%
Jun 30, 2025
MainStreet Advisors
20.00K
0%
--
--
Jun 30, 2025
Watts Gwilliam & Co LLC
20.00K
0%
--
--
Jun 30, 2025
Private Advisor Group LLC
15.00K
0%
--
--
Jun 30, 2025
Dimensional Fund Advisors, L.P.
9.21K
0%
--
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Bristol-Myers Squibb Co的前五大股东是谁？
Bristol-Myers Squibb Co 的前五大股东如下：
International Assets Investment Management, LLC持有股份：175.00，占总股份比例：0.00%。
Transcend Capital Advisors, LLC持有股份：109.17K，占总股份比例：0.00%。
Davenport Asset Management持有股份：83.97K，占总股份比例：0.00%。
BofA Global Research (US)持有股份：51.83K，占总股份比例：0.00%。
Purkiss Capital Advisors LLC持有股份：26.45K，占总股份比例：0.00%。
International Assets Investment Management, LLC持有股份：175.00，占总股份比例：0.00%。
Transcend Capital Advisors, LLC持有股份：109.17K，占总股份比例：0.00%。
Davenport Asset Management持有股份：83.97K，占总股份比例：0.00%。
BofA Global Research (US)持有股份：51.83K，占总股份比例：0.00%。
Purkiss Capital Advisors LLC持有股份：26.45K，占总股份比例：0.00%。
Bristol-Myers Squibb Co的前三大股东类型是什么？
Bristol-Myers Squibb Co 的前三大股东类型分别是：
其他
其他
有多少机构持有Bristol-Myers Squibb Co(CELG_r)的股份？
截至2025Q4，共有32家机构持有Bristol-Myers Squibb Co的股份，合计持有的股份价值约为423.55K，占公司总股份的--%。与2025Q3相比，机构持股有所增加，增幅为--。
哪个业务部门对Bristol-Myers Squibb Co的收入贡献最大？
在--，--业务部门对Bristol-Myers Squibb Co的收入贡献最大，创收--，占总收入的--%。
